scholarly journals The Resistance and the Gene Homology to Clinical Isolates of Acinetobacter Calcoaceticus-Baumannii

2011 ◽  
Vol 5 (1) ◽  
pp. 39-48
Author(s):  
Fen Xie ◽  
Yong-Juan Ding ◽  
Xia-Lan Zhang ◽  
Juan Lü ◽  
Jian-Qiang Li ◽  
...  
Keyword(s):  
Acinetobacter Calcoaceticus ◽  
Clinical Isolates ◽  
Gene Homology

scholarly journals Comparison of Genospecies and Antimicrobial Resistance Profiles of Isolates in the Acinetobacter calcoaceticus-Acinetobacter baumannii Complex from Various Clinical Specimens

2012 ◽  
Vol 56 (12) ◽  
pp. 6267-6271 ◽  
Author(s):  
Ni Tien ◽  
Bang-Jau You ◽  
Hui-Lan Chang ◽  
Hsiu-Shen Lin ◽  
Chin-Yi Lee ◽  
...  
Keyword(s):  
Antimicrobial Resistance ◽  
Acinetobacter Baumannii ◽  
Restriction Analysis ◽  
Acinetobacter Calcoaceticus ◽  
Its Region ◽  
Clinical Isolates ◽  
23S Rrna ◽  
Rrna Gene ◽  
Genotype 3 ◽  
Content Type

ABSTRACTThis study was conducted to compare the prevalences of antimicrobial resistance profiles of clinical isolates in theAcinetobacter calcoaceticus-Acinetobacter baumanniicomplex from sterile and nonsterile sites and to further study the relationship of antimicrobial resistance profiles and genospecies by amplified rRNA gene restriction analysis (ARDRA). A total of 1,381 isolates were tested with 12 different antibiotics to show their antimicrobial susceptibility profiles. A total of 205 clinical isolates were further analyzed by ARDRA of the intergenic spacer (ITS) region of the 16S-23S rRNA gene. It was found that the overall percentage of isolates from nonsterile sites (urine, sputum, pus, or catheter tip) that were resistant to the 12 antibiotics tested was significantly higher than that of isolates from sterile sites (cerebrospinal fluid [CSF], ascites fluid, and bloodstream) (46% versus 22%;P< 0.05). After ARDRA, it was found that 97% of the 62 isolates resistant to all antibiotics tested were theA. baumanniigenospecies, which was identified in only 31% of the isolates susceptible to all antibiotics tested. More genospecies diversity was identified in the isolates susceptible to all antibiotics tested, including genospecies of 13TU (34%), genotype 3 (29%), andA. calcoaceticus(5%). Furthermore, as 91% (10/11) of the isolates from CSF were susceptible to all antibiotics tested, theA. calcoaceticus-A. baumanniicomplex isolates with multidrug resistance could be less invasive than the more susceptible isolates. This study also indicated current emergence of carbapenem-, fluoroquinolone-, aminoglycoside-, and cephalosporin-resistantA. calcoaceticus-A. baumanniicomplex isolates in Taiwan.

scholarly journals Validation of partial rpoB gene sequence analysis for the identification of clinically important and emerging Acinetobacter species

Microbiology ◽  
2009 ◽  
Vol 155 (7) ◽  
pp. 2333-2341 ◽  
Author(s):  
Vijay A. K. B. Gundi ◽  
Lenie Dijkshoorn ◽  
Sophie Burignat ◽  
Didier Raoult ◽  
Bernard La Scola
Keyword(s):  
Sequence Analysis ◽  
Acinetobacter Calcoaceticus ◽  
Rpob Gene ◽  
Public Hospitals ◽  
Clinical Isolates ◽  
Acinetobacter Species ◽  
Promising Target ◽  
Gene Sequence Analysis ◽  
Routine Identification ◽  
Respective Type

Bacteria belonging to the genus Acinetobacter are ubiquitous in soil and water. Only a few species, including Acinetobacter baumannii, and the unnamed Acinetobacter genomic species (gen. sp.) 3 and 13TU, which together with the soil organism Acinetobacter calcoaceticus are combined in the A. calcoaceticus–A. baumannii (Acb) complex, have been recognized as important nosocomial infectious agents. The ecology, epidemiology and pathology of most species are not yet well established. Lack of practical and accurate methods limits routine identification of clinical isolates and thus hampers precise identification of those of the Acb complex and other Acinetobacter species of possible clinical significance. We previously identified a 350 bp highly variable zone on the rpoB gene which appeared to be a promising target for rapid molecular identification. In the present study, we validated this method for accuracy on a collection of reference strains belonging to A. calcoaceticus (5 strains), Acinetobacter gen. sp. 3 (29 strains), A. gen. sp. 13TU (18 strains), A. baumannii (30 strains) and one strain each of A. radioresistens, A. gen. sp. 15TU, A. gen. sp. 10, A. gen. sp. 11, A. gen. sp. ‘between 1 and 3’ and A. gen. sp. 14TU=13BJ. This represents the largest analysis to date that compares a large number of well-identified strains of the Acb complex to assess the intra- and interspecies variation within this complex. All were correctly identified with 98.9–100 % intraspecies relatedness based on partial rpoB sequence analysis. We then applied this tool to identify 99 Acinetobacter clinical isolates from four public hospitals in Marseille, France. All isolates could easily be identified to species as they were separated into 13 species sequence types with a sequence variance of 0–2.6 % from their respective type strains. Of these 99 isolates, 10 were A. haemolyticus, 52 were A. baumannii, 27 were A. gen. sp. 3, 5 were A. schindleri, 1 was A. lwoffii, and 1 was A. gen. sp. 13TU. Three were provisionally identified as A. gen. sp. 9. This is the first work to identify all specimens of a set of clinical Acinetobacter isolates at species level using rpoB sequence analysis. Our data emphasize the recognition of A. schindleri as an emerging cause of Acinetobacter-related infection and confirm that A. gen. sp. 3 is the second most commonly isolated Acinetobacter species after A. baumannii in patients.

scholarly journals 1187. Retrospective and Prospective Analysis of Acinetobacter Modern-Day Clinical Isolates in a Large Mid-West Hospital System

2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S358-S359
Author(s):  
Juan Calix ◽  
Carey-Ann D Burnham ◽  
Mario Feldman
Keyword(s):  
United States ◽  
Acinetobacter Calcoaceticus ◽  
Patient Characteristics ◽  
The United States ◽  
Clinical Findings ◽  
Clinical Isolates ◽  
Prospective Analysis ◽  
Hospital System ◽  
Anatomic Distribution ◽  
Tissue Of Origin

Abstract Background The epidemiology of contemporary Acinetobacter calcoaceticus-baumannii complex (AcbC) strains in the United States is understudied. In addition to increasing multidrug resistance, there is concern that the rates of AcbC infections acquired outside of hospitals and the anatomic distribution of these infections may differ from what is previously reported. Furthermore, the epidemiology of non-AcbC clinical isolates is poorly characterized. Methods We retrospectively identified all cases associated with Acinetobacter clinical isolates in the Barnes-Jewish/Children’s Hospital system (St. Louis, MO) from 2007 to 2017. First isolates were classified as AcbC or non-AcbC. Tissue of origin, hospital-day of isolation, and antibiotic resistance profiles were determined. Results were compared with an ongoing prospective analysis of Acinetobacter isolates in the same system, started in July 2017. Results We identified 2,959 and 1,243 cases associated with AcbC and non-AcbC isolates, respectively. In both groups, isolates were most commonly obtained from respiratory (34% and 30% of total isolates) and connective tissue (34% and 27% of total isolates) sites. Urinary tract specimens were more likely to occur among AcbC isolates compared with non-AcBC isolates (664/2,959 [22%] vs. 147/1,243 [12%], P &lt; 0.001). The percentage of isolates obtained prior to hospital-day-2 are 62% and 78% for AcbC and non-AcbC isolates, respectively. AcbC isolates were markedly more resistant to all classes of antibiotics. Analysis of 77 AcbC and 58 non-AcbC prospectively collected isolates revealed similar clinical findings. Conclusion Our study confirms the protean nature of Acinetobacter clinical isolates, and begins to describe relevant differences between AcbC and non-AcbC strains. These distinctions support the practice of identifying clinical isolates using AcbC and non-AcbC labels. Ongoing studies will further describe the patient characteristics and clinical outcomes associated with Acinetobacter disease in our system. Disclosures All authors: No reported disclosures.

Sign in / Sign up

Export Citation Format

Share Document